摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Ethyl-6-methylmorpholine | 59630-15-8

中文名称
——
中文别名
——
英文名称
2-Ethyl-6-methylmorpholine
英文别名
——
2-Ethyl-6-methylmorpholine化学式
CAS
59630-15-8
化学式
C7H15NO
mdl
MFCD11652902
分子量
129.2
InChiKey
JEIHFHDCQHZFAO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    174.0±15.0 °C(Predicted)
  • 密度:
    0.855±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES SPIROCYCLIQUES FUSIONNÉS POUR TRAITER LES INFECTIONS BACTÉRIENNES
    申请人:ASTRAZENECA AB
    公开号:WO2010043893A1
    公开(公告)日:2010-04-22
    The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及式(I)的化合物;其药学上可接受的盐;使用它们治疗细菌感染的方法;以及它们的制备方法。
  • [EN] NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES EN TANT QU'INHIBITEURS DE PI3-K ET DE MTOR
    申请人:CT NAC INVESTIGACIONES ONCOLOGICAS CNIO
    公开号:WO2011141713A1
    公开(公告)日:2011-11-17
    There is provided compounds of formula (I), wherein A1, A4, A4a,A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    提供了化合物的公式(I),其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3的含义如描述所示,并且其药学上可接受的酯、酰胺、溶剂合物或盐,这些化合物在治疗需要或期望抑制蛋白激酶或脂质激酶(如PI3-K和/或mTOR)的疾病中具有用处,特别是在治疗癌症或增殖性疾病方面。
  • [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE ET LEURS UTILISATIONS
    申请人:INTEGRAL BIOSCIENCES PVT LTD
    公开号:WO2021019514A1
    公开(公告)日:2021-02-04
    The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.
    本公开涉及一般用于治疗与检查点激酶(CHK)相关疾病的化合物,特别是CHK-1酶。具体地,本发明揭示了式(IA)的化合物,该化合物对CHK-1酶具有抑制活性。公开了使用这些化合物治疗与CHK-1酶过度活性相关的疾病的方法。还公开了这些化合物的用途、制药组合物、试剂盒和合成方法。
  • FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    申请人:Barvian Kevin
    公开号:US20110245224A1
    公开(公告)日:2011-10-06
    The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及式(I)的化合物;其药学上可接受的盐;使用它们治疗细菌感染的方法;以及它们的制备方法。
  • P13K ISOFORM SELECTIVE INHIBITORS
    申请人:Liang Congxin
    公开号:US20110130395A1
    公开(公告)日:2011-06-02
    2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    2-吗啡啉-4-基-9H-嘌呤和5-吗啡啉-4-基-3H-[1,2,3]三唑[4,5-d]嘧啶生物,特别是那些被6-杂环芳基取代的衍生物,是意外的PI3K酶亚型选择性抑制剂,具有良好的药物特性,并可用于治疗与异常PI3K活性相关的疾病,如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经系统疾病。
查看更多